Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
INJECTAPAP vs SELEXIPAG
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Acetaminophen is a centrally acting analgesic and antipyretic; its exact mechanism is not fully understood but involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system and modulation of descending serotonergic pathways. It does not have significant anti-inflammatory activity.
Selective agonist of the prostacyclin (IP) receptor, causing vasodilation and inhibition of platelet aggregation via increased c AMP levels.
Management of mild to moderate pain,Reduction of fever
Treatment of pulmonary arterial hypertension (PAH; WHO Group I) to improve exercise capacity and delay clinical worsening.
1 g intravenous every 6 hours or 650 mg intravenous every 4 hours; maximum 4 g per day.
Oral, starting dose 200 mcg twice daily, titrated in increments of 200 mcg twice daily at weekly intervals as tolerated to a maximum of 1600 mcg twice daily.
2-3 hours in adults; prolonged to 4-6 hours in neonates and patients with hepatic impairment.
Terminal elimination half-life is approximately 6–8 hours following intravenous administration; with oral administration, the effective half-life is ~6–9 hours due to enterohepatic recirculation; clinical context: dosing every 6 hours is required to maintain therapeutic plasma concentrations.
Primarily metabolized in the liver via conjugation (glucuronidation and sulfation) at therapeutic doses; a minor pathway via cytochrome P450 (CYP2E1, CYP1A2, and CYP3A4) produces a toxic metabolite (NAPQI) which is normally detoxified by glutathione.
Primarily metabolized by CYP2C8 and CYP3A4; minor contribution from UGT1A3, UGT2B7, and CYP2C9.
Renal: 2-5% unchanged; hepatic metabolism to glucuronide and sulfate conjugates, then renal excretion of metabolites. Biliary/fecal: minimal (<5%).
Primarily hepatic metabolism (approximately 97% of dose) via CYP2C8 and CYP3A4; biliary/fecal excretion of metabolites accounts for ~77% of total clearance; renal excretion <1% as unchanged drug.
10-25% bound to albumin at therapeutic concentrations.
Approximately 99% bound to plasma proteins, primarily albumin.
0.8-1.0 L/kg; suggests distribution into total body water.
Volume of distribution at steady state is approximately 1.7 L/kg (range 1.1–2.5 L/kg), indicating extensive extravascular distribution.
IV: 100%; oral: 60-90% (first-pass metabolism); rectal: 30-50%.
Oral bioavailability is approximately 90% under fed conditions; absorption is delayed and reduced by high-fat meals, but overall systemic exposure is increased by ~30% compared to fasting.
For GFR 30-60 m L/min: no adjustment; for GFR <30 m L/min: extend interval to every 8 hours; maximum 3 g per day.
No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (e GFR <15 m L/min/1.73 m²) or on dialysis; use with caution.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%, maximum 2 g per day; Child-Pugh C: contraindicated.
Contraindicated in Child-Pugh class C. For Child-Pugh class A or B, reduce starting dose to 200 mcg once daily and titrate cautiously; monitor closely.
For weight ≥50 kg: 1 g every 6 hours; for weight 10-50 kg: 15 mg/kg every 6 hours; for weight <10 kg: 7.5 mg/kg every 6 hours; all intravenous.
Not approved for pediatric use; safety and efficacy not established.
No specific dose adjustment required; consider decreased hepatic function and concomitant medications; maximum 3 g per day for patients with risk factors for hepatotoxicity.
No specific dose adjustment recommended; initiate at 200 mcg twice daily and titrate based on tolerability, considering increased sensitivity and comorbidities.
Acetaminophen has been associated with cases of acute liver failure, hepatotoxicity is primarily due to overdose. Risk is increased in patients with underlying liver disease, chronic alcohol use, and those taking multiple acetaminophen-containing products.
Not recommended for use in patients with severe hepatic impairment (Child-Pugh class C).
Risk of hepatotoxicity, especially with doses exceeding 4 g/day or in patients with liver impairment,Severe skin reactions including Stevens-Johnson syndrome, toxic epidermal necrolysis, and acute generalized exanthematous pustulosis,Hypersensitivity reactions,Use caution in patients with G6PD deficiency,Avoid use with other acetaminophen-containing products
Elderly patients may have increased exposure.,Patients with hepatic impairment: dose adjustment required for moderate impairment; avoid in severe impairment.,Concomitant use with strong CYP2C8 inhibitors (e.g., gemfibrozil) increases selexipag exposure by 11-fold; reduce dose.,Concomitant use with strong CYP3A4 inducers (e.g., rifampin) reduces exposure; monitor efficacy.,May cause headache, diarrhea, jaw pain, flushing, and nausea.
Hypersensitivity to acetaminophen or any component of the formulation
Severe hepatic impairment (Child-Pugh class C).,Concomitant use with strong CYP2C8 inhibitors (e.g., gemfibrozil).
No significant food interactions. However, concurrent ingestion of alcohol may increase risk of hepatotoxicity; avoid alcohol while on therapy.
Take with food to improve tolerance. Avoid grapefruit and grapefruit juice as they may increase selexipag plasma concentrations. No other significant food interactions known.
FDA Category C. Acetaminophen crosses the placenta. No evidence of teratogenicity in humans with standard doses. First trimester: limited data suggest no increased risk of major malformations. Second and third trimesters: chronic high-dose use may be associated with increased risk of childhood asthma and attention-deficit/hyperactivity disorder (ADHD). Overdose poses risk of maternal and fetal hepatotoxicity.
Selexipag is contraindicated in pregnancy. Animal studies show increased post-implantation loss and reduced fetal weights. No adequate human data; based on its mechanism (IP receptor agonist), risk of fetal harm cannot be excluded, particularly in the first trimester.
Acetaminophen is excreted into breast milk in low concentrations (M/P ratio approximately 0.91-1.42). Reported infant dose is less than 2% of maternal weight-adjusted dose. Considered compatible with breastfeeding. Use lowest effective dose for shortest duration.
No data on selexipag in human milk. In animal studies, selexipag is excreted in rat milk. M/P ratio unknown. Breastfeeding is not recommended during treatment and for at least 7 days after last dose.
No dose adjustment required for standard therapeutic use. Increased clearance in pregnancy may require shorter dosing intervals for pain control; consider maximum daily dose of 3 g/day instead of 4 g/day. Avoid prolonged use >48 hours without medical supervision.
Selexipag is not recommended in pregnancy. No dose adjustment data exist; pharmacokinetics in pregnancy have not been studied. Theoretical changes in volume of distribution and hepatic clearance may require monitoring, but no specific adjustments are established.
Acetaminophen injection is indicated for treatment of acute pain and fever. Use with caution in hepatic impairment. Avoid in patients with severe active liver disease. Monitor liver function tests with prolonged use. Do not exceed maximum daily dose (4 g/day in adults). Use the smallest effective dose for the shortest duration.
Selexipag is a prostacyclin receptor (IP receptor) agonist used for pulmonary arterial hypertension (PAH). It is a prodrug that requires hepatic carboxylesterase 1 (CES1) activation. Monitor for signs of pulmonary edema suggestive of pulmonary veno-occlusive disease. Concurrent use with strong CYP2C8 inhibitors (e.g., gemfibrozil) increases exposure and is contraindicated. Dose adjustment needed in moderate hepatic impairment (Child-Pugh B). Thyroid abnormalities and bleeding risk are potential concerns.
Do not take more than the recommended dose. Overdose can cause severe liver damage.,Inform your healthcare provider if you have liver disease or drink alcohol regularly.,Check other medications for acetaminophen to avoid double dosing.,Seek immediate medical attention if you experience signs of liver injury (e.g., yellowing skin/eyes, dark urine, upper stomach pain).,This medication is administered by intravenous infusion; do not attempt self-administration.
Take selexipag exactly as prescribed, typically twice daily with food to reduce gastrointestinal side effects.,Do not crush or chew tablets; swallow whole.,Common side effects include headache, diarrhea, nausea, jaw pain, and muscle aches; report persistent or severe symptoms.,Avoid grapefruit juice as it may increase drug levels.,Inform your doctor if you experience signs of bleeding (unusual bruising, nosebleeds) or thyroid issues (fatigue, weight changes).,Do not stop abruptly without medical advice; sudden discontinuation may worsen PAH.,If you are taking gemfibrozil or other CYP2C8 inhibitors, discuss with your doctor as combination is contraindicated.,Women of childbearing potential should use effective contraception; discuss pregnancy planning with your doctor.
No interactions on record
"Hydrochlorothiazide, a thiazide diuretic, reduces blood pressure primarily by decreasing plasma volume and cardiac output, while Selexipag, a prostacyclin receptor agonist, causes vasodilation and inhibits platelet aggregation. Their concomitant use results in additive hypotensive effects, increasing the risk of symptomatic hypotension, dizziness, and syncope. This interaction is particularly significant in patients with compromised baroreflex function or those receiving other antihypertensives."
"Selexipag, a prostacyclin receptor agonist used for pulmonary arterial hypertension, is primarily metabolized by CYP2C8 and CYP3A4. Abiraterone, a CYP3A4 inhibitor, may reduce the clearance of selexipag, leading to increased selexipag exposure. This can potentiate its adverse effects such as headache, flushing, and hypotension, though the impact on abiraterone levels is minimal due to abiraterone's multiple metabolic pathways."
"Bretylium, an antiarrhythmic agent, exerts sympatholytic effects by blocking norepinephrine release from adrenergic nerve terminals, leading to peripheral vasodilation and potential hypotension. Selexipag, a prostacyclin receptor agonist used for pulmonary arterial hypertension, also induces vasodilation via activation of IP receptors in vascular smooth muscle. When coadministered, the vasodilatory effects are additive, increasing the risk of clinically significant hypotension, which may manifest as dizziness, syncope, or impaired organ perfusion."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about INJECTAPAP vs SELEXIPAG, answered by our medical review team.
INJECTAPAP is a Non-Opioid Analgesic that works by Acetaminophen is a centrally acting analgesic and antipyretic; its exact mechanism is not fully understood but involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system and modulation of descending serotonergic pathways. It does not have significant anti-inflammatory activity.. SELEXIPAG is a Prostacyclin Receptor Agonist that works by Selective agonist of the prostacyclin (IP) receptor, causing vasodilation and inhibition of platelet aggregation via increased c AMP levels.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between INJECTAPAP and SELEXIPAG depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of INJECTAPAP is: 1 g intravenous every 6 hours or 650 mg intravenous every 4 hours; maximum 4 g per day.. The standard adult dose of SELEXIPAG is: Oral, starting dose 200 mcg twice daily, titrated in increments of 200 mcg twice daily at weekly intervals as tolerated to a maximum of 1600 mcg twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between INJECTAPAP and SELEXIPAG in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. INJECTAPAP is classified as Category C. FDA Category C. Acetaminophen crosses the placenta. No evidence of teratogenicity in humans with standard doses. First trimester: limited data suggest no increased risk of major ma. SELEXIPAG is classified as Category C. Selexipag is contraindicated in pregnancy. Animal studies show increased post-implantation loss and reduced fetal weights. No adequate human data; based on its mechanism (IP recept. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.